An overview of oral bioavailability enhancement through self- emulsifying drug delivery systems.

Abstract

Introduction: The pharmaceutical technologists face a lot of challenges and limitations when designing novel drug delivery systems such as low oral bioavailability of many drugs, primarily due to poor solubility, slow dissolution rates, limited permeability through gastrointestinal mucosa, and rapid degradation within the body. Areas covered: The biopharmaceutical classification (BCS) classification represents a map in drug delivery research. Numerous active ingredients are characterized by low bioavailability due to poor water solubility, especially active ingredients of BCS class II and IV. Self-emulsifying drug delivery systems (SEDDS) could act as game changer in order to overcome the challenges and limitations of poor bioavailability. In this review, timelines representing the launch of self - emulsifying drug delivery systems, their introduction to the pharmaceutical platform and their benefits will be discussed in detail.

Expert opinion: The development of multifunctional systems capable of combining controlled release, targeted delivery, and diagnostic capabilities is a promising avenue. As the technology matures, self-microemulsifying drug delivery systems and self-nanomulsifiying drug delivery systems are likely to become a standard approach for delivering BCS class II and IV drugs, transforming the pharmaceutical landscape.